Study TypeCognitive Impairment & Alzheimer's Disease
Study PurposeThe A4 research study will test whether an investigational medication (Solanezumab) can slow down memory loss and prevent the development of Alzheimer’s disease.
About the StudyScientists believe a buildup of protein in the brain (called “amyloid plaque deposits”) may play a key role in the memory loss related to Alzheimer’s disease. The A4 study will observe whether decreasing amyloid plaque deposits, through the use of an investigational medication, can help slow memory loss and prevent the development of Alzheimer’s disease.
- 5 screening visits
- 43 study visits (including 36 monthly infusions)
- Physical and neurological examination
- Vital signs and blood tests
- Multiple questionnaires
- Diagnostic tests such as MRI, PET Scan and ECG
- Intravenous infusions (IV)
Number of Visits:
- Be 65 to 85 years old
- Have normal thinking and memory abilities
- Have a friend or family member willing to be your A4 study partner (someone who has at least weekly contact with you and can answer questions once a year)
- Be willing and able to receive IV infusions of the investigational medication or placebo for 36 months along with overall health monitoring
To qualify for the A4 research study, participants should:
Study DurationParticipation in this study will last approximately three years and nine months.
CompensationCompensation of up to $1700 is offered for completion of this study.
Study ContactIf you are interested in volunteering for the A4 research study call 225-763-2973 or email email@example.com.
For additional information on clinical trials by investigator or sponsor, please visit clinicaltrials.gov